Acadia was granted approval by … While Nuplazid's sales growth is definitely encouraging, the company's rather stretched valuation simply isn't attractive. What: Acadia Pharmaceuticals' (NASDAQ:ACAD) stock rose by nearly 10% last month, according to data from S&P Global Market Intelligence. Returns as of 07/30/2020.That's a big deal because AXS-05 would likely need to grab only about 4% of the MDD market to reach blockbuster status (assuming a typical pricing point for an antidepressant). The long and short of it is that investors are clearly betting that Acadia will attract a buyout offer soon.
post. Acadia is a very good buyout target but the valuation is a bit stretched lately. What happened. So a more typical penetration rate -- one that's easily achievable now with two big competitors down for the count -- would have the drug's peak sales coming in closer to $5 billion. Thanks to a hefty capital raise, the company exited the third quarter with $683.8 million in cash and investments. Posted 6 months ago 0. In Q3, for example, the company reported a whopping $72.7 million in SG&A expenses.Even so, the biopharma's stellar Q3 numbers failed to excite investors.
Thanks to improving sales for its Parkinson's disease psychosis (PDP) medicine Nuplazid and a … The fact is that we have been defining Acadia investment process for years knowing when to be short or long the stock. When the market opened, the stock was trading well into the red. We are building the foundation to become a leading biopharmaceutical company dedicated to developing and commercializing innovative therapies in the CNS area. Should investors change their tune toward Acadia's stock after this standout quarter, or is yesterday's muted reaction appropriate in light of the company's near-term outlook? In Q3, for example, the company reported a whopping $72.7 million in SG&A expenses.Even so, the biopharma's stellar Q3 numbers failed to excite investors.
Buyout on its way!! Dislike post Like post. In other words, Acadia could take two to perhaps three more years to turn into a red-hot takeover target. Acadia Pharmaceuticals and Neurocrine Biosciences stand out as potential takeover candidates among biotech stocks, an analyst said Friday.. X. @TheMarketsDaily Analysts Set Expectations for ACADIA Pharmaceuticals Inc.’s FY2021 Earnings $ACAD https://t.co/N7hpifH53f July 25 th 2020, 5:07am The long and short of it is that investors are clearly betting that Acadia will attract a buyout offer soon.
Unfortunately, there's no particularly good reason to believe that a suitor is waiting in the wings at this juncture.Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services.Another bright spot is Acadia's financial position. Vieira Last year headlines hit mainstream media after our call to buy Acadia ahead of FDA approval.
However, doctors are unlikely to switch from prescribing established pain medications unless Cara's alternatives are demonstrably superior, and that may be a high hurdle to vault, MarketWatch adds. The truly crazy part about this story, though, is that Axsome's other pipeline activities could tack on several billion in additional sales if things go according to plan.Biotechnology has proved to be one of the most fruitful areas when it comes to stocks that quickly double or even triple in value seemingly overnight. We entered 2017 with a Strong Buy rating on Acadia (ACAD) since our team upgraded it to Strong Buy at a price of $17 after predicting this biotech company crash last year. Thanks to a hefty capital raise, the company exited the third quarter with $683.8 million in cash and investments. From 5$ to
That's what usually follows when the ACAD stock is up 100% in the last month. That's the only thing being discussed on the StockTwits ACAD board. The real reason to trade or invest in Acadia Pharmaceuticals is not centered on a potential buyout.
Moreover, all of these companies are experiencing tremendous pressure from U.S. politicians to lower the prices of their brand name medications. Meanwhile, there's no guarantee the market will remain patient with the company's sky-high valuation.Stock Advisor launched in February of 2002. Biotech News Acadia Pharmaceuticals $ACAD Buyout the TRUTH. First off, the company is still losing tons of cash ($182.2 million during the first nine months of 2019), despite Nuplazid's strong commercial performance this year.